circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X JMP Securities Life Sciences Conference
    Jun 19, 2019 9:00 AM EDT

    JMP Securities Life Sciences Conference
    Jun 19, 2019 9:00 AM EDT
  • Webcast
    X Cytokinetics, Inc. Annual Shareholder Meeting
    May 15, 2019 10:30 AM PDT

    Cytokinetics, Inc. Annual Shareholder Meeting
    May 15, 2019 10:30 AM PDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
SOUTH SAN FRANCISCO, Calif. , July 23, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of spinal muscular atrophy (SMA). The U.S.
Toggle Summary Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
SOUTH SAN FRANCISCO, Calif. , July 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that two preclinical poster presentations relating to CK-3773274 (CK-274) will be presented at the American Heart Association’s Basic Cardiovascular Sciences (BCVS) Scientific
Toggle Summary Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Clinical Trial Enrolled Over 8,200 Patients With Reduced Ejection Fraction in 35 Countries SOUTH SAN FRANCISCO, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in GALACTIC-HF ( G lobal A pproach to L owering A
Toggle Summary Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
Two Studies Show Addition of Reldesemtiv to SMN-Directed Treatment Increases Muscle Force in Mouse Model of Spinal Muscular Atrophy SOUTH SAN FRANCISCO, Calif. , June 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from two preclinical studies of

EVENTS

There are currently no events to display.